Efficacy of Aflibercept for macular edema in our hospital

Efficacy of Aflibercept for macular edema - Efficacy of Aflibercept for macular edema

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000048108

Enrollment

300

Registered

2022-06-20

Start date

2021-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic macular edema, retinal vein occlusion

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients who go to the outpatient department of ophthalmology at Chiba University Hospital (2) Patients who received intra-vitreal injections of Aflibercept from January 2018 to December 2020 (3) Patients with diabetic macular edema or macular edema with retinal branch obstruction (4) Patients who received intra-vitrealinjections of Aflibercept 3 times or more

Exclusion criteria

Exclusion criteria: Patients who have not been followed up for more than 1 year

Design outcomes

Primary

Measure	Time frame
Central retinal thickness and best corrected visual acuity one month after the 3rd to 12th vitreal injection of Aflibercept	—

Countries

Japan

Contacts

Public ContactTomoaki Tatsumi

Chiba University Graduate School of Medicine Department of Ophthalmology and Visual Science

newyear98mt@yahoo.co.jp0432262124

Outcome results